Skip to main
SKIN

SKIN Stock Forecast & Price Target

SKIN Analyst Ratings

Based on 4 analyst ratings
Hold
Strong Buy 25%
Buy 0%
Hold 75%
Sell 0%
Strong Sell 0%

Bulls say

SkinHealth Systems is well positioned for long-term success, despite facing competitive pressures and ongoing legal obligations, given its strong niche in the non-invasive medical aesthetics market with its Hydrafacial brand. The company's recent financial results exceeded expectations, and the new CEO is taking proactive steps to manage the sales organization and develop new products. However, potential impediments to our price target include softening equipment demand and one-time expenses related to litigation and restructuring that may affect cash flow in the short term.

Bears say

SkinHealth Systems is facing several challenges that have resulted in a negative outlook for its stock. These include lowered revenue guidance for 2026, expiration of key patents, intense competition in the beauty industry, and declining consumable sales. Despite a strong 4Q performance, the company still faces challenges in its device sales and utilization, and it may take time to see consistent improvements. Additionally, macroeconomic factors and the company's heavy reliance on the Hydrafacial platform pose risks to its growth. These challenges may make it difficult for SkinHealth Systems to expand its customer base and sustain its brand awareness, leading to a negative outlook on the stock.

SKIN has been analyzed by 4 analysts, with a consensus rating of Hold. 25% of analysts recommend a Strong Buy, 0% recommend Buy, 75% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Beauty Health Company and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Beauty Health Company (SKIN) Forecast

Analysts have given SKIN a Hold based on their latest research and market trends.

According to 4 analysts, SKIN has a Hold consensus rating as of Jun 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1.52, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1.52, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Beauty Health Company (SKIN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.